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Abstract
Background: The incidence of ductal carcinoma in situ (DCIS) has rapidly increased over time. The malignant
potential of DCIS is dependent on its differentiation grade.
Methods: Our aim is to determine the distribution of different grades of DCIS among women screened in the mass
screening programme, and women not screened in the mass screening programme, and to estimate the amount of
overdiagnosis by grade of DCIS. We retrospectively included a population-based sample of 4232 women with a diagnosis
of DCIS in the years 2007–2009 from the Nationwide network and registry of histopathology and cytopathology in the
Netherlands. Excluded were women with concurrent invasive breast cancer, lobular carcinoma in situ and no DCIS,
women recently treated for invasive breast cancer, no grade mentioned in the record, inconclusive record on invasion,
and prevalent DCIS. The screening status was obtained via the screening organisations. The distribution of grades was
incorporated in the well-established and validated microsimulation model MISCAN.
Results: Overall, 17.7 % of DCIS were low grade, 31.4 % intermediate grade, and 50.9 % high grade. This distribution
did not differ by screening status, but did vary by age. Older women were more likely to have low-grade DCIS than
younger women. Overdiagnosis as a proportion of all cancers in women of the screening age was 61 % for low-grade,
57 % for intermediate-grade, 45 % for high-grade DCIS. For women age 50–60 years with a high-grade DCIS this
overdiagnosis rate was 21–29 %, compared to 50–66 % in women age 60–75 years with high-grade DCIS.
Conclusions: Amongst the rapidly increasing numbers of DCIS diagnosed each year is a significant number of
overdiagnosed cases. Tailoring treatment to the probability of progression is the next step to preventing overtreatment.
The basis of this tailoring could be DCIS grade and age.
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Background
Ductal carcinoma in situ (DCIS) is a “neoplastic prolifera-
tion of cells within the ductal-lobular structures of the
breast that has not penetrated the myoepithelial-basement
membrane interface” [1]. Before the introduction of mam-
mography screening, DCIS was rarely diagnosed. In 1989,
366 women in the Netherlands were diagnosed with
DCIS. In 2003, more than 10 years after the introduction
of mass screening, 1171 women had a DCIS diagnosed.
With the introduction of digital screening this figure rose
to 2046 women in 2011, and most recently to 2406 in
2014 [2].
The extent to which DCIS represents overdiagnosis
has been extensively debated in relation to organised
screening programmes [3–6]. Overdiagnosis is defined
as a lesion diagnosed by screening in an asymptomatic
woman that would not have been detected during the
woman’s lifetime in the absence of screening [4]. To pre-
dict the probability of a DCIS to progress to invasive
carcinoma, six different grading systems were proposed,
based on morphology or molecular profile [7]. All of
these classify DCIS into three categories of malignant
potential: low (I), intermediate (II), or high (III). The
grade of DCIS is correlated with the risk of progression,
as well as with the grade of concurrent invasive carcin-
oma [8–13]. The transition from low-grade DCIS to
high-grade DCIS or to high-grade invasive carcinoma is
deemed unlikely [8–10, 12].
The grade distribution of DCIS has been studied in
mostly small series [6, 14–18], or only included screen-
detected cases (Table 1) [19]. More insight in this distri-
bution based on larger numbers in both screened and
non-screened populations is of paramount importance
and may improve our estimates of overdiagnosis.
The aim of this study was to establish the distribution
of different grades of DCIS in different subgroups based
on mass screening status and age group, and to estimate
the overdiagnosis rate for each grade and age group
specifically.
Methods
Patient selection
We obtained 17,744 excerpts from 12,301 women with
DCIS from the years 2007, 2008 and 2009 from the
‘Nationwide network and registry of histopathology and
cytopathology in the Netherlands’ (PALGA). PALGA is a
national database containing the excerpts and coded
diagnoses of all pathological and cytological examina-
tions performed in the Netherlands [20]. The mass
screening status of these women was established by
linking the database to the databases of the screening
organisations by an independent third party, with the
permission of the screening organisations. Our database
contained anonymised records of mass screening status
(positive, negative, year of last mass screening and
number of mass screening examinations), age, year of
diagnosis, and a short summary of the conclusion of the
original pathology report.
From the 12,301 women, we excluded those who also
had a concurrent invasive breast cancer (ipsilateral or
contralateral, N = 7089), those who had a lobular carcin-
oma in situ and no DCIS (N = 6), those who turned out
after excision biopsy or ablation not to have any malig-
nancy (N = 131), those who had recently been treated for
invasive breast cancer (N = 247), those who had no grade
mentioned in the excerpt (N = 17), those who had an in-
conclusive excerpt on invasion or otherwise (N = 242),
and women who had a prevalent DCIS, rather than a
new diagnosis in the study period (N = 354). We ex-
cluded contralateral disease because our model does not
include bilateral disease.
Table 1 Grade distribution by detection mode and sample size compared to previous studies on DCIS grade distribution
Screen detected Symptomatic Not specified
DCIS
grade 1
DCIS
grade 2
DCIS
grade 3
DCIS
grade 1
DCIS
grade 2
DCIS
grade 3
DCIS
grade 1
DCIS
grade 2
DCIS
grade 3
% % % N % % % N % % % N
This study 16 32 52 1430 19 28 54 263
Evans 2001 [6] 13 18 69 222 16 23 61 151 - - - -
Kessar 2002 [15] 23 23 54 98 19 19 62 52 - - - -
Meijnen 2005 [16] 22 31 47 87 26 24 49 293 - - - -
de Roos 2007 [14] 7 44 53 54 30 45 25 20 - - - -
Sorum 2010 [18] - - - - - - - - 23 23 53 2403
Bluekens 2012 [19] 15 32 54 853 - - - - - - - -
Weigel 2015 [33] 18 39 42 898 - - - - - - - -
DCIS ductal carcinoma in situ
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DCIS detected by mass screening
DCIS were assumed to be ‘detected by mass screening’
when a woman had had a positive screening examination
between 2007 and 2009. Women who had participated
in the screening programme, and did not have any posi-
tive screens, but who did have a DCIS diagnosis in 2007,
2008, or 2009 were assumed to have an interval DCIS.
The number of interval DCIS increased across the study
period due to the cumulative effect of interval DCIS
diagnosed in women screened in the previous year
(2007) or in the 2 previous years (2007 and 2008). Inter-
val DCIS were rare in 2007 because of the low frequency
of interval carcinomas within the same calendar year in
which the screening examination took place. In 2008,
interval DCIS were diagnosed in women screened in
2007 or 2008, and in 2009, interval DCIS were diag-
nosed in women screened in 2007, 2008 or 2009.
Women who were not known to the screening organi-
sations may have been under clinical surveillance be-
cause of high familial risk, frequent (benign) breast
anomalies, or because of personal preference. Diagnoses
in this group may be the result of screening, but are not
the result of the mass screening programme. Therefore
we cannot conclude that DCIS not detected by mass
screening, were not detected by screening. To compare
the distribution of DCIS detected by mass screening to
DCIS not detected by mass screening, we, therefore,
chose to compare the DCIS detected by mass screening
to the interval DCIS.
Grading of DCIS
In line with the Dutch guidelines, the classification by
Holland et al. is almost exclusively used [21]. At the start
of the mass screening programme in the early 1990s,
pathologists were instructed on how to uniformly
classify each DCIS.
DCIS grade was determined using the information in
the short summary of the pathology report by descrip-
tion, i.e. high, moderate, or low differentiation; low,
intermediate, or high malignancy potential; or grade I, II,
or III. If the summary contained more than one grade,
this case was graded according to the highest grade
mentioned. If there was a discrepancy between grades in
different specimens of the same patient, the grade was
based on the most representative specimen, i.e. resection
is more representative than biopsy, but biopsy is more
representative than cytology.
Statistical analysis
Proportions of DCIS grades were calculated by year, age
group, and screening status. We compared these pro-
portions between screening groups using the Pearson
chi-square test. Multivariate analyses on age groups were
performed with a logistic regression model. The statistically
significant parameters were identified by the introduction
of variables in a stepwise manner. All calculations were
performed using IBM SPSS version 20.0 (IBM Corp.,
Armonk, NY, USA).
Modelling approach
The MISCAN model is a microsimulation model that
simulates the individual life histories of women [22].
The probability of each woman to have an onset of
breast cancer is determined by calibrating the model to
the incidence rate in 1989 (the year before screening was
introduced), adjusted with an annual percentage change
of 1.4 % to account for the rising background breast can-
cer incidence [23]. The natural history of breast cancer
is modelled as a Markov-like progression through the
successive preclinical stages of the disease. Details of the
model have been described previously [4]. For this ana-
lysis we added the three DCIS grades to the model,
using the age-dependent grade distribution found in this
study (Fig. 1).
Following onset, breast cancer in a preclinical stage
can progress to the next preclinical stage (dependent on
the duration of the previous state), or become clinically
detected. In addition, the DCIS stages may also regress
to normal [24, 25]. Screening is superimposed on this
life history.
The transition probabilities, duration of tumour stages,
and test sensitivities were calibrated using data from the
Dutch population and Dutch breast cancer screening
from 1975 to 2010 on breast cancer incidence by stage,
age, and detection mode. The Dutch nationwide breast-
cancer screening programme has invited all women aged
50–69 since 1990 and women aged 50–75 since 1998
biennially for a mammographic screening examination,
free of charge. The attendance rate is approximately
80 % [26].
We chose to look at model outcomes for the years
2000–2009 because there was a steady state situation in
these years, more than 10 years after the start of the
screening programme. We evaluated the following out-
put: incidence rate by detection mode (screen detected
or clinically detected), age, and year of diagnosis. The
model compares women in the situation with screening,
to the same women in the situation without screening; if
a woman has a screen-detected cancer, but would not
have had a diagnosis in the situation without screening,
this case is regarded as overdiagnosed (Fig. 2).
The estimates and definitions of overdiagnosis vary
widely among international publications [4]. To minim-
ise confusion, we used the definitions of overdiagnosis
which were deemed most useful by an independent
review panel in the UK; from a population perspective:
the proportion of all cancers ever diagnosed in women
of the screening age and over (50–100 years) that are
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Fig. 1 Schematic drawing of the extended MISCAN model. Transition possibilities are indicated with arrows. All diseases within the grey area are
preclinical disease, after diagnosis they are either clinically detected or detected by mass screening. There is no transition between low-grade
DCIS, intermediate-grade DCIS and high-grade DCIS. DCIS ductal carcinoma in situ, MISCAN MIcrosimulation SCreening ANalysis (predicted rates
by the model), T1a tumour with a diameter up to 5 mm, T1b tumour with a diameter from 5 mm up to 10 mm, T1c tumour with a diameter from
10 mm up to 20 mm, T2 + any tumour with a diameter larger than 20 mm
Fig. 2 Screening affecting three women differently. The first box is the life history of a woman who has an onset of breast cancer, is diagnosed
clinically, and dies of breast cancer. The second box is the life history of a woman who also has an onset of breast cancer, but who dies of other
causes before this would be detected. The third box is the life history of a woman who has an onset of breast cancer, but also a spontaneous
regression, this woman would not have been diagnosed without screening. The fourth box indicates the situation for these three women had
screening been introduced. The woman in the first box no longer dies from breast cancer; the other two women do not benefit from screening,
they have been overdiagnosed
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overdiagnosed; and from an individual perspective: the
proportion of all cancers ever diagnosed in women of the
screening age (50–75 years) that are overdiagnosed [27].
Assumptions on natural behaviour of DCIS
In the original model a 2 % regression rate, an 11 % pro-
gression rate, and a 5 % clinical detection rate was
assumed for all DCIS, resulting in a proper fit of incidence
[28]. Little is known about the natural history of DCIS
without treatment. Small studies were published, indicat-
ing a progression rate of one in two to one in three for
low-grade DCIS, one in three for intermediate-grade DCIS
and two in three in high-grade DCIS [29, 30]. Progression
rate may differ from the rate assumed in the original
model. In the new model we assumed that intermediate-
grade DCIS has the same transition probabilities as all
DCIS had in the original model. We lowered the regres-
sion rate to 1 % for high-grade DCIS, and increased the
regression rate to 4 % for low-grade DCIS, based on the
findings of Sanders et al. [30]. The probability for a DCIS
to be clinically detected was assumed independent of
grade. The probability of progression: 16 % for low-grade
DCIS, 31 % for intermediate-grade DCIS, and 53 % for
high-grade DCIS, was estimated by correcting the prob-
abilities of low-grade DCIS and high-grade DCIS by the
progression found in literature [29, 30]. Adjusting the pro-
gression rate and therefore the duration of the state, influ-
ences all successive states, because the progression of each
successive state is dependent on the duration of the
previous state. High-grade invasive breast cancer follows
high-grade DCIS and low-grade invasive breast cancer fol-
lows low-grade DCIS. We calibrated DCIS incidence rate
to observed data for the period 1990–2010.
Results
Patients/distribution of DCIS grade
Patient characteristics are summarised in Table 2. There
was no significant difference in the distribution of grades
between the DCIS detected by mass screening and the
DCIS not detected by mass screening (from the interval
group); 16.4–18.8 % were low grade, 27.2–31.6 % were
intermediate grade, and 52.0–54.0 % were high grade
(Table 3).
Univariate analysis of the group, not detected by mass
screening, showed that DCIS grade has an inverse linear
association with 5-year age group (P value = 0.015), and
with age as a linear variable (P value = 0.018). Year of
diagnosis did not contribute in this group. Overall the
year of diagnosis was a significant independent variable
(P value = 0.02) (Table 4).
Estimating overdiagnosis
The distribution of DCIS grade was included in the
model and the new model was calibrated estimating
dwell times and probabilities of transition on incidence
data from the Cancer Registry and grade distribution
from our study (Fig. 3).
Table 2 Descriptive statistics of the DCIS cases reviewed
Known at mass screening Not known at mass screening P value
N % N %
Patients 4.075 8.226
Exclusions 2.382 58 % 5.687 69 %
Inclusions 1.693 42 % 2.539 31 %
Year diagnosis
2007 429 25 % 865 34 % <0.001
2008 583 34 % 806 32 %
2009 681 40 % 868 34 %
Age group
<49 0 0 % 651 26 % <0.001
49–75 1.690 100 % 1.686 66 %
>75 3 0 % 202 8 %
Screen result
Positive screen 1.430 n.a.
No positive screen 263 n.a.
Mean Mean
Age 60.8 56.3 <0.001
‘Known at mass screening’ are all women who were listed in the database of the screening organisations with a positive or a negative screen, ‘Not known at mass
screening’ are all women who were not mentioned in the screening organisation’s database
DCIS ductal carcinoma in situ, n.a. not applicable
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Overdiagnosis estimates from the model were, from
the population perspective: 60 % of low-grade DCIS,
56 % of intermediate-grade DCIS, 45 % of high-grade
DCIS. Overdiagnosis estimates from the individual per-
spective were: 61 % of low-grade DCIS, 57 % of
intermediate-grade DCIS, 45 % of high-grade DCIS.
When stratified by age group, the younger women had a
much lower overdiagnosis rate when being diagnosed
with a high-grade DCIS, varying from 21 % in age group
50–55 to 29 % in age group 55–60, up to 66 % in age
group 70–75 (Table 5).
Discussion
This is the largest study on the distribution of DCIS
grade and the first modelling study to estimate overdiag-
nosis rate by DCIS grade. The distribution of grades in
Table 3 Distribution of different DCIS grades by screening status and age group
Detected at mass screening Screen negative P value
N % N %
Age group
<49 0 0
Low-grade DCIS 0 n.a. 0 n.a.
Intermediate-grade DCIS 0 n.a. 0 n.a.
High-grade DCIS 0 n.a. 0 n.a.
49–75 1429 261
Low-grade DCIS 234 16.4 % 49 18.8 %
Intermediate-grade DCIS 452 31.6 % 71 27.2 % 0.579
High-grade DCIS 743 52.0 % 141 54.0 %
>75 1 2
Low-grade DCIS 0 0.0 % 0 0.0 %
Intermediate-grade DCIS 0 0.0 % 2 100.0 % 0.297
High-grade DCIS 1 100.0 % 0 0.0 %
The P values indicate the significance of the difference of these distributions between screening status. Low-grade DCIS: DCIS with a low malignant potential.
Intermediate-grade DCIS: DCIS with an intermediate malignant potential. High-grade DCIS: DCIS with a high malignant potential
DCIS ductal carcinoma in situ, n.a. not applicable
Table 4 Distribution of different DCIS grades by year and screening status
Detected at mass screening Screen negative P value
N % N %
Year
2007 410 19
Low-grade DCIS 59 14.4 % 3 15.8 %
Intermediate-grade DCIS 109 26.6 % 2 10.5 % 0.083
High-grade DCIS 242 59.0 % 14 73.7 %
2008 525 58
Low-grade DCIS 91 17.3 % 11 19.0 %
Intermediate-grade DCIS 167 31.8 % 15 25.9 % 0.827
High-grade DCIS 267 50.9 % 32 55.2 %
2009 495 186
Low-grade DCIS 84 17.0 % 35 18.8 %
Intermediate-grade DCIS 176 35.6 % 56 30.1 % 0.651
High-grade DCIS 235 47.5 % 95 51.1 %
The P values indicate the significance of the difference of these distributions between screening status. Low-grade DCIS: DCIS with a low malignant potential.
Intermediate-grade DCIS: DCIS with an intermediate malignant potential. High-grade DCIS: DCIS with a high malignant potential
DCIS ductal carcinoma in situ
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DCIS is dependent on age, but not on mass screening
status. This is in accordance with earlier studies on
grade distribution. The overall distribution is also con-
sistent with these studies (Table 4) [6, 14–16, 18, 19, 31].
The incidence rate of DCIS has increased rapidly over
recent years. DCIS is unequivocally associated with
mammography screening. Approximately one third of
the cases in the database were detected by mass screen-
ing, which corresponds to the overall distribution of
breast cancers detected by mass screening (both in situ
and invasive) of all breast cancers in the Dutch popula-
tion, and to the findings of Shin et al. [32]. However, in
our study, when linking Dutch pathology reports to the
records of the screening organisations, most DCIS were
not known at mass screening organisations. This can
partly be explained by the fact that one of the nine orga-
nisations that were responsible for screening at the time
did not deliver data to be linked to the PALGA database.
This organisation represents approximately 15 % of all
screened women annually. Second, we do not know how
the diagnoses not detected by mass screening were
established. Given the age distribution and the fact that
DCIS is generally not palpable, we assume that the
Fig. 3 Low-grade DCIS, intermediate-grade DCIS and high-grade DCIS per 100,000 women aged 50–60. Observed: the number of DCIS as calculated
when applying DCIS grade distribution to the data on total DCIS incidence from the Dutch Cancer Registry. DCIS ductal carcinoma in situ, MISCAN
MIcrosimulation SCreening ANalysis (predicted rates by the model)
Table 5 Overdiagnosis estimates by two different definitions
Low-grade
DCIS
Intermediate-grade
DCIS
High-grade
DCIS
Population perspective 60 % 56 % 45 %
Individual perspective 61 % 57 % 45 %
Individual perspective
by age group
50–55 58 % 46 % 21 %
55–60 62 % 55 % 29 %
60–65 66 % 64 % 50 %
65–70 49 % 52 % 61 %
70–75 54 % 58 % 66 %
Population perspective: the proportion of all cancers ever diagnosed in
women of the screening age and over (50–100 years) that are overdiagnosed.
Individual perspective: the proportion of all cancers ever diagnosed in women
of the screening age (50–75 years) that are overdiagnosed. Low-grade DCIS:
DCIS with a low malignant potential. Intermediate-grade DCIS: DCIS with an
intermediate malignant potential. High-grade DCIS: DCIS with a high
malignant potential
DCIS ductal carcinoma in situ
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majority of these cases are diagnosed through screening
outside the mass screening programme.
As expected, and in line with previous studies, we
found more low-grade DCIS in older women [33]. In
general, more aggressive cancers are diagnosed earlier in
life. Those that remain for detection at an older age are
more likely to be less aggressive [34].
In the Netherlands, a transition to screening with digital
mammography was made between 2005 and 2010. In
2010, the detection rate of DCIS in mass screening
increased substantially, probably as a result of the intro-
duction of digital mammography screening. Currently, it
is not yet clear whether this is a prevalence effect or a last-
ing effect. We studied the years 2007, 2008 and 2009; thus,
an increasing proportion of the DCIS we considered has
been found with digital screening. We have no knowledge
which DCIS were detected by digital mammography or
film screen mammography. Also, the DCIS detected
outside the mass screening programme are equally likely
to have been detected with digital mammography. We did
not find a difference in grade distribution in screen-
detected DCIS over this period; therefore it seems unlikely
that digital screening will have significantly altered the
grade distribution, which is also in accordance with the
findings of Bluekens et al. [19].
We have found that grade distribution for DCIS in the
years 2007, 2008 and 2009, was inversely related to age,
but we have no information on historical development
of this distribution. For our study, we assumed the dis-
tribution to be stable over time.
Considerable controversy exists on whether DCIS is
the ideal stage of the disease for early detection, or
whether the detection of DCIS represents overdiagnosis,
and, consequently, overtreatment. However, agreement
exists that it is essential to determine which individual
diagnosis is overdiagnosis and which is not. Central to
this discussion is the natural behaviour of DCIS. Now
that we have specified grades of DCIS in the microsimu-
lation model, we can estimate overdiagnosis more accur-
ately. Only 16.4 % of DCIS detected by mass screening
are low grade, 60 % respectively 61 % of which are over-
diagnosed, depending on the definition of overdiagnosis.
We found that 50.9 % of all DCIS detected by mass
screening are high grade, and therefore have a high risk
of progression. In these cases we are bound to find
aggressive cancer earlier and to prevent fast-growing
invasive cancer, but even so, 45 % of these cases are
overdiagnosed, independent on the definition of overdi-
agnosis. For younger women (age 50–60) with a high-
grade DCIS however, overdiagnosis estimates vary
between 21 % and 29 % from an individual perspective,
therefore for these women screening is most protective.
We found an increasing amount of overdiagnosis in
older women with high-grade DCIS; this is the result of
a longer dwell time in the model in high-grade DCIS in
women over 60. This dwell time was calibrated by the
model. A disease with a longer dwell time is more likely
to be detected by screening. The longer dwell time of
high-grade DCIS in older women correlates to the find-
ings of Weigel et al., who found a higher detection rate
of high-grade DCIS in older women [33].
Our overdiagnosis estimates make a general decision
on treatment from a population-based approach a very
difficult one for women with DCIS. We estimate that
60 % of these women would be overtreated if they
undergo treatment for this disease, of which they would
never have been aware in the absence of screening. On
the other hand, they are diagnosed with an entity that
carries a specific risk for progression to an invasive and
potentially lethal disease and will therefore lean towards
treatment, rather than active surveillance. If this entity
would be named differently this might be perceived dif-
ferently [35]. DCIS can also be regarded as a risk factor
like lobular carcinoma in situ (LCIS). One can question
whether the increased risk in DCIS, as compared to LCIS,
justifies the current practice of invasive treatments.
Specific estimates for overdiagnosis rate by grade will
become increasingly important. These estimates may
change when the treatment for DCIS can be even more
customised according to grade [36]. To our knowledge,
a trial to compare treatment of DCIS to active surveil-
lance is planned [37].
Limitations of the study
We did not review grading or examine inter-observer
variation between pathologists, because this was beyond
the scope of our study. PALGA and the Dutch associ-
ation of pathologists will be conducting a study to evalu-
ate the inter-observer variation in the near future. We
believe our study to be a proper representation of the
current Dutch situation. There is no reason to suspect
that DCIS not detected by mass screening represents a
different patient group than DCIS detected by mass
screening, and for that reason, for both groups the same
dilemma with regard to a possible inter-observer vari-
ation exists.
Assumptions on behaviour of DCIS were done on older
studies. Advances have been made in the evaluation of
biopsies. Currently more sampling is done and patholo-
gists are more aware of the possible findings in DCIS, this
could influence the assumptions on behaviour of DCIS if
the studies on which they are based were repeated now.
Conclusions
DCIS grade is almost equally distributed across the
screened population in the breast cancer screening
programme and the population not subjected to/
participating in mass screening.
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DCIS has been divided into three grades, each consti-
tuting a unique entity with its own natural history. We
found that the distribution of these grades is not
dependent on mass screening status, but is dependent
on age. When taking the different grades into account,
overdiagnosis rates of breast cancer in mass screening
are 60 % for low-grade DCIS and 45 % for high-grade
DCIS from a population perspective, and 61 % and 45 %
respectively from an individual perspective. When taking
the younger ages and high grade into account overdiag-
nosis rate from an individual perspective is 21–29 %.
These figures underline the necessity of large rando-
mised trials for watchful waiting in low-grade DCIS,
whether these are detected in a mass screening programme
or not.
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